Prenosis was founded in 2014 to bring precision medicine to the highest-acuity settings in hospitals, where clinicians must make life-or-death decisions quickly and with incomplete information. Conditions like sepsis kill hundreds of thousands of patients each year and are notoriously hard to diagnose early because their signs overlap with many other illnesses. Prenosis approaches this by combining a proprietary biobank of richly annotated patient samples with machine learning to detect immune signatures that predict disease onset, severity, and trajectory.
The company's core technology, the Immunix platform, integrates biological, clinical, and molecular data to power a portfolio of AI-based diagnostics. Its flagship product, Sepsis ImmunoScore, became the first AI diagnostic tool for sepsis to receive FDA authorization, a landmark regulatory milestone that validates both the science and Prenosis's rigorous clinical development approach. The tool gives clinicians an objective, integrated risk score to identify sepsis earlier and intervene faster.
Beyond sepsis, Prenosis is extending its precision medicine platform to additional critical care conditions including pneumonia, acute heart failure, acute respiratory distress syndrome, and acute kidney injury. The long-term vision is to build an integrated diagnostics-and-therapeutics network for critical care, where the same biological understanding that powers diagnosis also informs which treatments will work for which patients.
In early 2026, Prenosis announced a combined $40 million in new capital: a $20 million Series A led by PACE Healthcare Capital, with co-investors including UC Investments, the Labcorp Venture Fund, and Global Health Investment Corporation, alongside a $20 million contract from the Biomedical Advanced Research and Development Authority (BARDA). The funding supports commercial deployment, clinical trial enrollment, algorithm development, and regulatory expansion.
Founder and CEO Bobby Reddy, Jr. was named to TIME's 2025 TIME100 Health list for his work advancing AI in critical care. With FDA authorization in hand and a clear pipeline of additional conditions, Prenosis is positioned as a pioneer in AI-driven acute care diagnostics.